News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Penn Engineering Welcomes Vanessa Chan as Inaugural Vice Dean of Innovation and Entrepreneurship
Chan brings a wealth of experience in bridging the gap between groundbreaking ideas and real-world impact to her new role at Penn.
Philadelphia’s Biotech Ecosystem Bolstered as WuXi AppTec Deal Eases Congressional Pressure
WuXi AppTec sold its South Philly-based Advanced Therapies contract manufacturing unit to New York-based healthcare investment firm Altaris LLC.
PCI’s John Swartley Nominated as BioBuzz Leader of the Year Finalist
John Swartley, MBA, PhD, Penn’s Chief Innovation Officer, was named as a finalist for BioBuzz Leader of the Year in Greater Philadelphia.
Berger Lab Makes Discovery Linking cellular structures to kidney cancer treatment outcomes
These findings could pave the way for personalized treatments, matching patients to drugs based on their tumor's speckle pattern.
Mitchell Lab Develops a lipid nanoparticle with the potential to deliver an mRNA-based treatment for preeclampsia
The technology addresses a critical health equity gap for pregnant individuals with preeclampsia.
iECURE Reports on Preliminary Clinical Response Data in First Infant Dosed with its in vivo Gene Editing Candidate ECUR-506
iECURE reported preliminary findings from the first infant dosed with its in vivo gene editing candidate ECUR-506.
Sahay AI Wins 1682 Venture Award for Most Promising AI-Driven Startups in Philadelphia
Sahay AI won the 1682 Venture Award, a pitch competition for early-stage AI-driven startups based in Philadelphia.
Penn Awarded NSF AIRFoundry Grant to Meld AI and RNA
The goal of the NSF AIRFoundry is to make cutting-edge RNA research accessible to the broader scientific community to empower scientists to tackle some of the world’s biggest challenges,
ViTToria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of its VIPER-101 T-Cell Therapy
ViTToria has dosed the first patient in its Phase 1 clinical trial for VIPER-101.
āshibio Moves Forward with Clinical Trial
āshibio announced the dosing of the first participant in its Phase 2/3 clinical trial for its lead candidate, andecaliximab.